Rectal spacers in patients with prostate cancer undergoing radiotherapy: A survey of UK uro-oncologists

Amit Bahl, Amarnath Challapalli, Suneil Jain, Heather Payne

Research output: Contribution to journalArticlepeer-review


To understand the awareness and use of rectal spacers for prostate cancer patients undergoing radical radiotherapy in the UK. An expert-devised online questionnaire was completed by members of the British Uro-oncology Group (BUG). Sixty-three specialists completed the survey (50% of BUG members at that point in time). Only 37% had used rectal spacers, mostly for private patients or those with pre-existing bowel conditions. However, many (68%) would like to use these devices in future. More than 70% of the uro-oncologists felt that bowel toxicity was under-reported, but 60% believed that the use of radiotherapy without bowel toxicity was achievable with the use of rectal spacers. The current use of rectal spacers by UK uro-oncologists for patients with localised or locally advanced prostate cancer receiving radiotherapy is low and largely restricted by resourcing issues. [Abstract copyright: This article is protected by copyright. All rights reserved.]
Original languageEnglish
Article numbere14338
JournalInternational Journal of Clinical Practice
Early online date09 May 2021
Publication statusEarly online date - 09 May 2021


  • bowel toxicity
  • prostate cancer
  • radical radiotherapy
  • rectal spacer


Dive into the research topics of 'Rectal spacers in patients with prostate cancer undergoing radiotherapy: A survey of UK uro-oncologists'. Together they form a unique fingerprint.

Cite this